Corporate Governance

BASi® Board of Directors

 

Gregory C. Davis, Ph.D.
Dr. Gregory C. Davis was elected to the board on June 14, 2017. Dr. Davis currently runs his own consulting firm, which he founded in 2012, assisting companies with regulatory and control strategy and product development issues. In 2014, Dr. Davis joined Calibrium, LLC as Vice President of CMC, Regulatory, and Quality. Calibrium was developing novel biotheraputics for the treatment of diabetes. The company was sold to Novo Nordisk in late 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in Biotechnology Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. One of the highlights of his Lilly career was being COO of the Xigris Product Team. Xigris was the first biotechnology product ever approved for the treatment of severe sepsis. When Dr. Davis retired from Eli Lilly in December of 2012, he was Executive Director and Senior Principle Fellow in Global Regulatory Affairs.

Dr. Davis has held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. He coauthored several of the ICH guidances on registration standards for biotechnology products, which are still in use today. Dr. Davis received his bachelor’s degree from Southeast Missouri State University and his Ph.D. in Analytical Chemistry from Purdue University studying under Dr. Peter Kissinger, founder of BASi.


Richard A. Johnson, Ph.D.
Dr. Johnson retired from his position as President of AvTech Laboratories, Inc. in 2008. He founded the company in 1990 as an independent contract pharmaceutical testing laboratory which provided contract testing services to major research-based pharmaceutical companies. Dr. Johnson sold AvTech to Eurofins Scientific in October of 2005. Prior to launching AvTech, Dr. Johnson worked for 19 years in a variety of positions for the Upjohn Company; such as Strategic Planning, Quality Assurance, and Product Control. Dr. Johnson earned his Bachelors of Science in Chemistry from the Illinois Institute of Technology and his Ph.D. in Chemical Physics from Michigan State University.


R. Matthew Neff

R. Matthew Neff was elected to the board on August 1, 2017. Mr. Neff is currently Of Counsel with Bingham Greenebaum Doll LLP’s Corporate and Transactional Department. From August 2013 through June 2016, Mr. Neff served as Chairman, President and Chief Executive Officer of AIT Laboratories, a national toxicology lab headquartered in Indianapolis, Indiana. Mr. Neff joined AIT Laboratories after his tenure as President and Chief Executive Officer of CHV Capital, Inc., the venture capital subsidiary of Indiana University Health, a role he had held since 2007.

Mr. Neff started his career as a practicing lawyer and Partner at Baker & Daniels. He then served as the Deputy to the Chairman of the Federal Housing Finance Board (now known as the Federal Housing Finance Agency) in the first Bush Administration. Thereafter, he became the co-founder and Chief Executive Officer of two Indianapolis companies: Circle Investors, an insurance holding company then chaired by former Vice President of the United States, Dan Quayle, and Senex Financial Corp., a healthcare receivables finance company. Mr. Neff currently serves on the Board of Directors of Fairbanks Addiction Treatment Center and was a member of Riley Children’s Foundation’s Board of Directors from January 2000 to November 2012.

Mr. Neff earned his bachelor’s degree and graduated a Phi Beta Kappa from DePauw University. He also received his Juris Doctor degree from Indiana We are pleased to welcome Mr. Neff to the Board and look forward to working with him. His strong Categories: Regional Business News, Pharmaceuticals and Biotech, Healthcare and Medical News, Research, Medical Research, Publicly Traded Tags: BASi, board, board of directors, contract research, NASDAQ, pharmaceutical, pharmaceutical industry, pharmaceutical research, press release, publicly traded, R. Matthew Neff University School of Law, where he was the Executive Editor of the Indiana Law Review.


Wendy Perrow, MBA
Wendy Perrow was elected as a director of the Company on December 10, 2015. Ms. Perrow is President and Chief Executive Officer at Alba Therapeutics. Ms. Perrow joined Alba Therapeutics in 2008 as Vice President, Business Development, Marketing and Alliance Management. She was appointed President and Chief Operating Officer in 2011 and named Chief Executive Officer in 2013. Prior to joining Alba Therapeutics, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc. From 1989 to 2003, Ms. Perrow held positions at Merck and Co., Inc. in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. Ms. Perrow holds a bachelor’s degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business.


Standing Committees

Audit Committee
R. Matthew Neff, Chair
Gregory C. Davis
Richard A. Johnson
Wendy Perrow

Compensation and Incentive Stock Option Committee
Wendy Perrow, Chair
Gregory C. Davis
Richard A. Johnson

Nominating and Governance Committee
Richard A. Johnson, Chair
Gregory C. Davis
Wendy Perrow

 

Charters